用于代谢和神经精神途径非致幻调节的取代色胺的设计与评估
Design and Evaluation of Substituted Tryptamines for Nonpsychedelic Modulation of Metabolic and Neuropsychiatric Pathways.
作者信息
Kargbo Robert B
机构信息
Usona Institute, Fitchburg, Wisconsin 53711-5300, United States.
出版信息
ACS Med Chem Lett. 2025 May 16;16(6):942-944. doi: 10.1021/acsmedchemlett.5c00263. eCollection 2025 Jun 12.
Abstract
Substituted tryptamines with selective 5-HTA/C activity demonstrate therapeutic promise without psychedelic effects. Two recent patent applications describe nonhallucinogenic analogs for metabolic and neuropsychiatric disorders. These agents exhibit optimized receptor selectivity, metabolic synergy, and neuroplastic potential, offering a novel chemical framework for multimodal treatment strategies.
摘要
具有选择性5-HTA/C活性的取代色胺显示出治疗前景且无迷幻作用。最近的两项专利申请描述了用于代谢和神经精神疾病的非致幻类似物。这些药物表现出优化的受体选择性、代谢协同作用和神经可塑性潜力，为多模式治疗策略提供了一种新的化学框架。
相似文献
1
Design and Evaluation of Substituted Tryptamines for Nonpsychedelic Modulation of Metabolic and Neuropsychiatric Pathways.用于代谢和神经精神途径非致幻调节的取代色胺的设计与评估
ACS Med Chem Lett. 2025 May 16;16(6):942-944. doi: 10.1021/acsmedchemlett.5c00263. eCollection 2025 Jun 12.
2
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
3
Liquid chromatography-tandem mass spectrometry-based pharmacokinetic and metabolic analysis of 4-bromo-2,5-dimethoxyphenethylamine and its metabolites in human plasma.基于液相色谱-串联质谱法的4-溴-2,5-二甲氧基苯乙胺及其代谢物在人血浆中的药代动力学和代谢分析
Drug Metab Dispos. 2025 Jun;53(6):100086. doi: 10.1016/j.dmd.2025.100086. Epub 2025 Apr 28.
4
Advances in Psychedelic Therapeutics: Novel Prodrugs and Derivatives for Enhanced Mental Health Treatment.迷幻疗法的进展：用于改善心理健康治疗的新型前药和衍生物
ACS Med Chem Lett. 2024 Nov 11;15(12):2071-2073. doi: 10.1021/acsmedchemlett.4c00519. eCollection 2024 Dec 12.
5
Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT) Receptor (5-HTR), 5-HTR, 5-HTR, and Serotonin Transporter.取代色胺类药物在 5-羟色胺（5-HT）受体（5-HTR）、5-HTR、5-HTR 和血清素转运体上的药理活性。
J Pharmacol Exp Ther. 2023 Apr;385(1):62-75. doi: 10.1124/jpet.122.001454. Epub 2023 Jan 20.
6
Bioproduction of a Large-Scale Library of Tryptamine Derivatives for Neuropsychiatric Drug Screening.
ACS Chem Biol. 2025 Jun 20;20(6):1212-1231. doi: 10.1021/acschembio.4c00857. Epub 2025 May 15.
7
Clinical Practice Updates: AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review.临床实践更新：美国胃肠病学会关于可弯曲性埃勒斯-当洛综合征的胃肠道表现及自主神经或免疫功能障碍的临床实践更新：专家综述
Clin Gastroenterol Hepatol. 2025 May 19. doi: 10.1016/j.cgh.2025.02.015.
8
Chemical Strategies to Modulate and Manipulate RNA Epigenetic Modifications.调控和操纵RNA表观遗传修饰的化学策略
Acc Chem Res. 2025 Jun 3;58(11):1727-1741. doi: 10.1021/acs.accounts.4c00844. Epub 2025 Mar 18.
9
Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.致幻剂辅助治疗对患有危及生命疾病的人群的焦虑、抑郁和存在性困扰的治疗作用。
Cochrane Database Syst Rev. 2024 Sep 12;9(9):CD015383. doi: 10.1002/14651858.CD015383.pub2.
10
Serotonin receptor 5-HT as a potential target for HCC immunotherapy.血清素受体5-HT作为肝癌免疫治疗的潜在靶点。
J Immunother Cancer. 2025 Jun 23;13(6):e011088. doi: 10.1136/jitc-2024-011088.
本文引用的文献
1
The Emergence of Psilocybin in Psychiatry and Neuroscience.裸盖菇素在精神病学和神经科学领域的兴起。
Pharmaceuticals (Basel). 2025 Apr 9;18(4):555. doi: 10.3390/ph18040555.
2
From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence-Based Policy and Practice.从疗效到效果：评估迷幻药随机对照试验以获取可靠的循证政策与实践依据
Pharmacol Res Perspect. 2025 Apr;13(2):e70097. doi: 10.1002/prp2.70097.
3
Neuroplasticity and psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models.神经可塑性与迷幻剂：对经典和非经典化合物在临床前及临床模型中的全面考察。
Neurosci Biobehav Rev. 2025 May;172:106132. doi: 10.1016/j.neubiorev.2025.106132. Epub 2025 Apr 2.
4
Utilizing Psychedelics to Enhance Well-Being: A Systematic Review.利用迷幻剂提升幸福感：一项系统综述。
J Psychoactive Drugs. 2025 Mar 31:1-17. doi: 10.1080/02791072.2025.2484380.
5
Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes.微剂量服用麦角酸二乙酰胺和裸盖菇素的副作用：对潜在生理和精神结果的系统评价
Neuropharmacology. 2025 Jun 15;271:110402. doi: 10.1016/j.neuropharm.2025.110402. Epub 2025 Mar 7.
6
Emerging Medications for Treatment-Resistant Depression: A Review with Perspective on Mechanisms and Challenges.治疗抵抗性抑郁症的新兴药物：机制与挑战视角的综述
Brain Sci. 2025 Feb 6;15(2):161. doi: 10.3390/brainsci15020161.
Zotero 插件